Sanifit raise €72.2m to push SNF472 development
Sanifit has bagged €72.2m in Spain’s largest private biotech fundraise.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2084 entries already.
Entries by Thomas Gabrielczyk
Genfit in $228m deal with Terns Pharmaceuticals
Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor to Terns Pharmaceuticals Inc.
Vesalius Biocapital III Fund closes at €120 million
Life sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at €120m.
Erytech Pharma SA bags US$57m from SQZ Biotechnologies
Erytech Pharma has inked a deal with SQZ Biotechnologies Inc. to develop new immune modulating therapies.
Sanofi/Regeneron’s IL-33 blocker meets endpoint in POC study
Sanofis and Regenerons IL-33 blocker REGN3500 met primary Phase II endpoint in asthma patients.
Researchers and bioethicists to pause germline editing
After the birth of the first genome-edited babies in China, regulators, researchers, and bioethics experts seek ways to ban clinical use of germline editing, in order to protect the innovative field from misuse for human enhancement and side effect-prone application forgene correction and human enhancement.
Karo Pharma acquires Trimb AB
Karo Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (€319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (€141m).
UK biotech to make proteins from carbon dioxide emissions
Deep Branch Biotechnology Ltd. from Nottingham has started a feasibility study with the British energy supplier Drax Group. The technology to be analysed converts carbon dioxide emitted by power stations into protein that could be used for feeding fish and livestock.
GM proponents grill German government
German GM proponents have taken action against discrimination of food products generated by gene editing.
Human cell chip predicts chemotherapy effects
Roche and US company Hesperos Inc have used human cancer and organ cells, placed in a 5-chamber microfluidic chip, to predict chemotherapy safety and efficacy preclinically.